Monday, August 3, 2015

Trevena lands ex-Wyeth R&D head for its board of directors

Robert Ruffolo, who retired from Wyeth less than a year ago, agreed to become more involved with the King of Prussia start-up that's working on treatments for cardiovascular and CNS disorders.

Trevena lands ex-Wyeth R&D head for its board of directors


Thanks to the concentration of pharmaceutical companies and medical research here, the Philadelphia region creates new life-sciences companies all the time.

Every start-up or spin-off starts full of promise and expectations for its technology. What distinguishes some is the amount of capital they raise or the management and scientific talent they attract.

One King of Prussia biotechnology firm yesterday added a “rock star.” Trevena Inc. named Robert R. Ruffolo Jr., the retired president of R&D at Collegeville-based Wyeth Pharmaceuticals to its seven-member board of directors.

Trevena, which raised $24 million in venture capital 13 months ago, is working on treatments for cardiovascular and central nervous systems disorders.

Its technology is licensed from Duke University Medical Center and based on research from the labs of Robert J. Lefkowitz and Howard A. Rockman.

In a statement, Ruffolo called the work underway at Trevena “tremendously exciting” and praised the management team as “first rate.” Trevena CEO Maxine Gowen had been the former head of GlaxoSmithKline’s Center of Excellence for External Drug Discovery.

Trevena currently has 21 employees, said company spokesman Alastair Southwell.

Ruffolo, who confessed in a 2005 profile in the Inquirer to playing in a garage band, also said Trevena was the first biotech board seat he’s accepted since retiring from Wyeth less than a year ago.


At first I was disappointed that I was not returning to Blank Rome, a firm I cherish and helped build. But we all close and open chapters in our lives every day and I look forward to starting my next chapter with Cozen O’Connor.

- David Girard-diCarlo, the former U.S. Ambassador to Austria, in a statement about returning to join the Philadelphia law firm of Cozen O’Connor rather than the firm he ran for more than 20 years.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter